Acadian Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-329,793
| Closed | -$9K | – | 1878 |
|
|
2025
Q1 | $9K | Buy |
329,793
+80,367
| +32% | +$13.6K | ﹤0.01% | 1562 |
|
|
2024
Q4 | $55K | Buy |
249,426
+196,560
| +372% | +$236K | ﹤0.01% | 1441 |
|
|
2024
Q3 | $113K | Buy |
52,866
+18,288
| +53% | +$65.7K | ﹤0.01% | 1550 |
|
|
2024
Q2 | $178K | Buy |
34,578
+17,416
| +101% | +$91.5K | ﹤0.01% | 1449 |
|
|
2024
Q1 | $91K | Buy |
+17,162
| New | +$119K | ﹤0.01% | 1305 |
|
|
2023
Q2 | – | Sell |
-12,776
| Closed | -$34K | – | 1946 |
|
|
2023
Q1 | $34K | Sell |
12,776
-4,966
| -28% | -$19.3K | ﹤0.01% | 1578 |
|
|
2022
Q4 | $62K | Sell |
17,742
-6,823
| -28% | -$29.6K | ﹤0.01% | 1538 |
|
|
2022
Q3 | $156K | Buy |
24,565
+10,871
| +79% | +$88.3K | ﹤0.01% | 1268 |
|
|
2022
Q2 | $132K | Buy |
13,694
+5,459
| +66% | +$51.1K | ﹤0.01% | 1297 |
|
|
2022
Q1 | $97K | Buy |
+8,235
| New | +$147K | ﹤0.01% | 1368 |
|
|
2021
Q3 | – | Sell |
-35,445
| Closed | -$1.93M | – | 2070 |
|
|
2021
Q2 | $1.93M | Buy |
+35,445
| New | +$2.1M | 0.01% | 717 |
|
|
2021
Q1 | – | Sell |
-1,165
| Closed | -$126K | – | 2364 |
|
|
2020
Q4 | $126K | Buy |
1,165
+696
| +148% | +$63.5K | ﹤0.01% | 1684 |
|
|
2020
Q3 | $41K | Sell |
469
-5,134
| -92% | -$583K | ﹤0.01% | 1908 |
|
|
2020
Q2 | $598K | Buy |
+5,603
| New | +$503K | ﹤0.01% | 1137 |
|
|
2020
Q1 | – | Sell |
-2,641
| Closed | -$182K | – | 1964 |
|
|
2019
Q4 | $182K | Buy |
+2,641
| New | +$160K | ﹤0.01% | 1317 |
|
|
2019
Q2 | – | Sell |
-1,079
| Closed | -$99K | – | 2077 |
|
|
2019
Q1 | $99K | Buy |
+1,079
| New | +$75.1K | ﹤0.01% | 1526 |
|
|
2018
Q4 | – | Sell |
-553
| Closed | -$66K | – | 1857 |
|
|
2018
Q3 | $66K | Sell |
553
-2,270
| -80% | -$263K | ﹤0.01% | 1300 |
|
|
2018
Q2 | $288K | Buy |
2,823
+2,784
| +7,138% | +$345K | ﹤0.01% | 998 |
|
|
2018
Q1 | $5K | Buy |
+39
| New | +$4.26K | ﹤0.01% | 1620 |
|
Acadian Asset Management's SYRS Position: Q2 2025 in Review
Acadian Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2025, closing a stake of 329,793 shares — an estimated $9K sold.
Acadian Asset Management first reported a position in SYRS in Q1 2018 and held it in 19 quarters. The position peaked at $1.93M in Q2 2021. 0 funds tracked by Wall St. Rank hold SYRS as of Q2 2025.
- Acadian Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Acadian Asset Management sold 329,793 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2025, an estimated $9K.
- Acadian Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 19 quarters.
- Acadian Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.93M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2025.
Based on Acadian Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.